IL314114A - Compositions and methods for the treatment of mesothelin-positive types of cancer - Google Patents

Compositions and methods for the treatment of mesothelin-positive types of cancer

Info

Publication number
IL314114A
IL314114A IL314114A IL31411424A IL314114A IL 314114 A IL314114 A IL 314114A IL 314114 A IL314114 A IL 314114A IL 31411424 A IL31411424 A IL 31411424A IL 314114 A IL314114 A IL 314114A
Authority
IL
Israel
Prior art keywords
compositions
methods
positive cancers
mesothelin positive
treating mesothelin
Prior art date
Application number
IL314114A
Other languages
English (en)
Hebrew (he)
Inventor
Carl Alexander Kamb
Agnes E Hamburger
Talar Tokatlian
Grace E Asuelime
Dora Toledo Warshaviak
Original Assignee
A2 Biotherapeutics Inc
Carl Alexander Kamb
Agnes E Hamburger
Talar Tokatlian
Grace E Asuelime
Dora Toledo Warshaviak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc, Carl Alexander Kamb, Agnes E Hamburger, Talar Tokatlian, Grace E Asuelime, Dora Toledo Warshaviak filed Critical A2 Biotherapeutics Inc
Publication of IL314114A publication Critical patent/IL314114A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL314114A 2022-01-28 2023-01-27 Compositions and methods for the treatment of mesothelin-positive types of cancer IL314114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263304409P 2022-01-28 2022-01-28
PCT/US2023/011698 WO2023147019A2 (en) 2022-01-28 2023-01-27 Compositions and methods for treating mesothelin positive cancers

Publications (1)

Publication Number Publication Date
IL314114A true IL314114A (en) 2024-09-01

Family

ID=87472570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314114A IL314114A (en) 2022-01-28 2023-01-27 Compositions and methods for the treatment of mesothelin-positive types of cancer

Country Status (10)

Country Link
US (1) US20250269027A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469559A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025503967A (cg-RX-API-DMAC10.html)
KR (1) KR20240155391A (cg-RX-API-DMAC10.html)
CN (1) CN119403921A (cg-RX-API-DMAC10.html)
AU (1) AU2023213691A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243381A1 (cg-RX-API-DMAC10.html)
IL (1) IL314114A (cg-RX-API-DMAC10.html)
MX (1) MX2024009338A (cg-RX-API-DMAC10.html)
WO (1) WO2023147019A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026527004A (ja) * 2023-08-02 2026-08-10 エー2 バイオセラピューティクス, インコーポレイテッド Hla-a*03の発現の喪失を伴うがんを治療するための組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504696A (zh) * 2017-09-15 2019-03-22 上海恒润达生生物科技有限公司 靶向人源化mesothelin的嵌合抗原受体的方法和用途
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
WO2020190483A1 (en) * 2019-03-15 2020-09-24 Rutgers, The State University Of New Jersey Cd147 chimeric antigen receptors and methods of use
SG11202112676VA (en) * 2019-05-16 2021-12-30 Memorial Sloan Kettering Cancer Center Mesothelin cars and uses thereof
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021119489A1 (en) * 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2022040454A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers

Also Published As

Publication number Publication date
CN119403921A (zh) 2025-02-07
WO2023147019A3 (en) 2023-09-14
EP4469559A4 (en) 2025-12-03
MX2024009338A (es) 2024-08-09
US20250269027A1 (en) 2025-08-28
KR20240155391A (ko) 2024-10-28
JP2025503967A (ja) 2025-02-06
CA3243381A1 (en) 2023-08-03
EP4469559A2 (en) 2024-12-04
WO2023147019A2 (en) 2023-08-03
AU2023213691A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
HUE067417T2 (hu) Készítmények és módszerek EGFR-pozitív rákok kezelésére
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
IL300067A (en) Preparations and methods for the treatment of cancers
ZA202104870B (en) Methods and compositions for treating cancer
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
IL315800A (en) Preparations and methods for the treatment of cancer
IL287982A (en) Preparations and methods for the treatment of cancer
GB2623930B (en) Probiotic compositions for treating and preventing colorectal cancer
IL286153A (en) Methods and preparations for the treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
GB202306292D0 (en) Methods and compositions for cellular therapy
IL308530A (en) Preparations and methods for treating lung cancer
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
AU2021372482A9 (en) Compositions and methods for treating hematopoietic malignancy
IL299039A (en) Methods and preparations for the treatment of triple-negative breast cancer
EP4149508A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
IL312846A (en) Methods and preparations for the treatment of cancer
IL290834A (en) Preparations and methods for the treatment of extensive stage small cell lung cancer (es-sclc)
EP4031253A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYC-ASSOCIATED CANCERS
IL319403A (en) Compositions and methods for treating advanced solid tumors
HK40085800A (en) Compositions and methods for treating mesothelin positive cancers
IL285036A (en) Methods and preparations for the treatment of cancer
GB202104635D0 (en) Methods and compositions for identifying and treating GCN2-dependent cancers